Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Alumis Stockholders Approve Merger with ACELYRIN
-
Alumis and ACELYRIN Announce Amended Merger Agreement
-
Alumis and ACELYRIN file joint definitive proxy statement for proposed merger, expected to close in 2Q 2025
-
Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan
-
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
-
Alumis to Present at Leerink's 2025 Global Healthcare Conference
-
ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025
-
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
-
Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026
-
Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases